Investor Relations


Press Release

Cytori to Address Nasdaq Listing via Nasdaq Hearing Panel

Dec 11, 2015

SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that it has received formal confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that Cytori’s request for an oral hearing with the Nasdaq Hearing Panel (“Panel”) has been granted. The hearing will occur on January 21, 2016 at Nasdaq’s Washington, D.C. offices. During the period prior to the hearing, Cytori’s common stock will continue to trade on The Nasdaq Global Market (“NGM”). Cytori intends to present a plan to the Hearing Panel that will allow it to remain on the NGM. As an alternative, Cytori believes that it is fully eligible to transfer to The Nasdaq Capital Market (“NCM”), in which case it would be entitled to rely on a second 180-day period (retroactively measured from December 1, 2015). During this second 180-day period, if required Cytori will be in a position to effect a reverse stock split to bring the bid price of its common stock above the minimum $1 threshold.

As Cytori reported on December 7, 2015, it received a determination letter from the Nasdaq staff stating that it has yet to regain compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Marketplace Rule 5450(a)(1). Upon receipt of the determination letter, Cytori chose to pursue a hearing in front of the Hearing Panel rather than seek an immediate transfer to the NCM because management believes that pursuing a hearing allows it the opportunity to present a comprehensive plan to regain compliance with NGM continued listing requirements.

About Cytori

Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information: visit

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements that involve known and unknown risks and uncertainties. All statements, other than historical facts are forward looking statements. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include Cytori’s ability to cause its common stock to remain listed on The Nasdaq Stock Market, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, included in our annual and quarterly reports.

There may be events in the future that we are unable to predict, or over which we have no control, and our business, financial condition, results of operations and prospects may change in the future. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless we have an obligation under U.S. Federal securities laws to do so.

Source: Cytori Therapeutics, Inc.

Cytori Therapeutics, Inc.

Tiago Girao, 1 (858) 458.0900